Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03897803
Other study ID # BenhaU2022019
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 15, 2019
Est. completion date November 1, 2020

Study information

Verified date October 2020
Source Benha University
Contact Waleed Hassan, MD
Phone 01095000886
Email waleed22101979@yahoo.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of our study was to assess the performance of compression-strain US elastography in patients with idiopathic inflammatory myopathies over time and to study these findings with clinical and functional parameters as well as biochemical and electromyographic tests.


Description:

This study will be carried out on four groups: Group (I): twenty children diagnosed to have idiopathic inflammatory myopathies(IIM) - Group (II): twenty adults diagnosed to have IIM - Group (III):20 healthy children matching age and sex as first control group to children with IIM . - Group (VI):20 healthy adults matching age and sex as second control group to adults with IIM. All patients will be evaluated at baseline at & 4-months follow up using Semi-Quantitative strain elastography


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date November 1, 2020
Est. primary completion date November 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: - to fulfill criteria of diagnosis of childhood and adult idiopathic inflammatory myopathies Exclusion Criteria: - Patients with age less than 2 years were excluded from the study due to inability to perform manual muscle testing and functional scales. - The presence of a associated illness that may result in nerve or muscle affection

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
strain elastography
strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.

Locations

Country Name City State
Egypt Benha University Hospital Banha Qalubiya

Sponsors (1)

Lead Sponsor Collaborator
Benha University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Manual muscle testing Kendall's 0 -10 point scale measures strength of each muscle group score 0 is the weakest (worst) and 10 is the strongest (best). The following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors(FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA) 6 months
Primary Serum creatine kinase (CK) levels CK measured in U/L using ELISA 6 months
Primary Serum Lactate dehydrogenase (LDH) levels LDHmeasured in IU/L using ELISA 6 months
Primary alanine aminotransferase (ALT) ALT measured in U/L using ELISA 6 months
Primary Aspartate aminotransferase (AST) AST measured in U/L using ELISA 6 months
Primary motor unit potential (MUP) duration quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the MUP duration measured in milliseconds. 6 months
Primary motor unit peak-to-peak amplitude quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the peak-to-peak amplitude measured in microvolt 6 months
Primary motor unit area to amplitude ratio (AAR) quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the motor unit AAR . 6 months
Primary muscle echo intenisity (EI) EI is assessed during muscle ultrasound evaluation means of computer-assisted grayscale histogram analysis of Adobe Photoshop . echo intensity was calculated based on a histogram analysis which expresses every pixel as a value between 0 (black) and 255 (white)..he following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors(FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA) 6 MONTHS
Primary Childhood myositis assessment scale used to assess the severity of muscle involvement in children with dermatomyositis. The scores for the 14 items are summated to give a total score ranging from 0 (worst) to 52 (best) 6 months
Primary MYOSITIS DISEASE ACTIVITY ASSESSMENT TOOL (MDAAT) The MDAAT is a combined tool that includes the Myositis Disease Activity Assessment visual analog scale (VAS) (MYOACT) and the Myositis Intention to Treat Activities Index (MITAX).it Assesses 6 extramuscular organs to produce a global extramuscular score, and the muscle score, which gives a total disease activity index score. Scores range from 0-60 for the extramuscular MYOACT score and 0-70 for the total MYOACT score, and they range from 0-54 for the Extramuscular MITAX score and 0-63 for the total MITAX score. higher scores indicates worse outcome 6 months
Primary CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ) There are 30 items in the Disability Index; one item each in the Discomfort Index and Health Status Index. Score range. The range is 0-3. Higher scores reflect greater disability. 6 months
Primary HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) 20 questions grouped into eight subscales (dressing and grooming, arising, eating, walking, hygiene, reach, grip, activities). (score = 0 to 3 with higher score means worse outcome ). The highest score for any question determines the score for the subscale in question. The HAQ disability index is calculated as the sum of the scores for various subscales,divided by the number of subscales responded to, and results in a score between 0 and 3. higher score means worse outcome 6months
Primary MYOSITIS DAMAGE INDEX (MDI) The MDI measures specific manifestations in 11 organ systems The MDI also includes a series of visual analog scales (VAS) to quantify damage severity in a given organ system. The VAS are summed together for a potential score of 0-110 with higher scores has worse prognosis 6months
Primary PHYSICIAN GLOBAL ACTIVITY assessment visual analogue scale rating, a score of 0-10 (down to 1 decimal place) is used, higher score means worse outcome 6 months
Primary PATIENT/PARENT GLOBAL ACTIVITY assessment visual analogue scale rating, a score of 0-10 (down to 1 decimal place) is used, higher score means worse outcome 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05833711 - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy Phase 2
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT04208464 - JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM Phase 2
Completed NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT06316076 - Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases Phase 1
Not yet recruiting NCT06350110 - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Recruiting NCT04792931 - Adult Autoimmune Myopathies (MAIA) N/A
Not yet recruiting NCT06417398 - Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Early Phase 1
Not yet recruiting NCT06285539 - Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Phase 2
Recruiting NCT04664465 - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Not yet recruiting NCT06152172 - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 Phase 1
Recruiting NCT05400889 - Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies Phase 2
Completed NCT03918356 - Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies N/A
Completed NCT00341679 - Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
Recruiting NCT05952531 - Characterizing Myositis With 68Ga-FAPI PET/CT Early Phase 1
Recruiting NCT05200702 - Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders N/A
Completed NCT03092167 - Physical Training in Patients With Idiopathic Inflammatory Myopathies N/A
Recruiting NCT03092180 - Optimizing Treatment on Idiopathic Inflammatory Myopathies
Recruiting NCT05199246 - Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders N/A